The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate

The Early Rheumatoid Arthritis (ERA) trial compared monotherapy with etanercept or methotrexate in patients with early erosive rheumatoid arthritis. Over the initial period of 12, and subsequently 24, months both treatments were associated with a profound reduction in radiographic progression of joi...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2003-09, Vol.21 (5 Suppl 31), p.S195
Main Authors: Bathon, J M, Genovese, M C
Format: Article
Language:English
Subjects:
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Controlled Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Administration Schedule
Etanercept
Female
Follow-Up Studies
Humans
Immunoglobulin G - administration & dosage
Immunoglobulin G - adverse effects
Male
Maximum Tolerated Dose
Methotrexate - administration & dosage
Methotrexate - adverse effects
Receptors, Tumor Necrosis Factor - administration & dosage
Risk Assessment
Severity of Illness Index
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Early Rheumatoid Arthritis (ERA) trial compared monotherapy with etanercept or methotrexate in patients with early erosive rheumatoid arthritis. Over the initial period of 12, and subsequently 24, months both treatments were associated with a profound reduction in radiographic progression of joint damage, as well as a reduction in signs and symptoms of disease. Etanercept showed slight superiority to methotrexate in reducing subsequent radiographic erosions and in the rapidity of the clinical response. Both therapies proved to be safe and well tolerated and, importantly, the relative safety and tolerance of a rapidly escalated dosing regimen for methotrexate was demonstrated. In summary, early aggressive treatment of RA is associated with clinical and radiographic benefit that can be demonstrated after a relatively short period of treatment.
ISSN:0392-856X